Role of rituximab as neoadjuvant therapy in a difficult case of relapsing pulmonary alveolar proteinosis.

Vikas Marwah, Robin Choudhary, Bhargava V Devarakonda, Virender Malik

Abstract readCase Reports

In one paragraph

Article in Medical journal, Armed Forces India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vikas MarwahProfessor & Head (Pulmonary, Critical Care & Sleep Medicine), Army Institute of Cardio Thoracic Sciences (AICTS), Pune, India.

Robin ChoudharySenior Resident (Pulmonary, Critical Care & Sleep Medicine), Army Institute of Cardio Thoracic Sciences (AICTS), Pune, India.

Bhargava V DevarakondaAssociate Professor (Cardiothoracic Vascular Surgery Anaesthesia), Army Institute of Cardio Thoracic Sciences (AICTS), Pune, India.

Virender MalikAssistant Professor (Radiology), Army Institute of Cardio Thoracic Sciences (AICTS), Pune, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disease which involves the accumulation of insoluble lipoproteinaceous material in the alveoli leading to impaired gas exchange and even respiratory failure. Autoimmune PAP is the most common type and is characterized by the presence of anti-granulocyte-monocyte colony stimulating factor (anti GM-CSF) antibody. Whole lung lavage has been traditionally used as first-line management of PAP but there is a lack of clarity especially in the treatment of relapsing cases of PAP. Rituximab is an anti Cluster of Differentiate 20 (CD 20) monoclonal antibody that has been tried as salvage therapy for relapsing cases of PAP. We present a case of 35 years old female patient who was diagnosed as a case of relapsing PAP who was managed initially with neoadjuvant rituximab. This is a retrospective observational report showing novel use of neoadjuvant rituximab in a difficult case of relapsing PAP.

Indexed as

Anti GM-CSF antibodiesNeoadjuvant therapyPulmonary alveolar proteinosisRituximabWhole lung lavage

Identifiers

PMID38800001

DOI10.1016/j.mjafi.2022.10.005

PMCPMC11116989

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.